| Trials |
Participants |
n |
Drugs |
Controls |
Mean Follow-up |
Background ACEI |
Outcomes |
|
| ADEPT 2001 (20) |
NYHA II–IV, LV EF  35% |
36 |
Eprosartan 400 mg BID |
Placebo |
8 weeks |
Yes |
Primary: EF; secondary; hemodynamics, neurohormones |
| Crozier 1995 (19) |
NYHA II–IV, LV EF <40%, PCWP  13 mm Hg |
134 |
1) Losartan 2.5 mg OD; 2) losartan 10 mg OD; 3) losartan 25 mg OD; 4) losartan 50 mg OD |
Placebo |
12 weeks |
No |
Primary: PCWP; secondary; clinical status, tolerability |
| Dickstein 1995 (27) |
NYHA III–IV, LV EF 35% |
166 |
1) Losartan 25 mg OD, 2) losartan 50 mg OD |
Enalapril 10 mg BID |
8 weeks |
No |
Primary: exercise capacity, clinical status, neurohumoral activation |
| ELITE 1997 (28) |
NYHA II–IV, LV EF 40%, no prior ACEI, age 65 |
722 |
Losartan 50 mg OD |
Captopril 50 mg TID |
48 weeks |
No |
Primary: renal dysfunction; secondary: all-cause mortality, HF hospitalization |
| ELITE II 2000 (5) |
NYHA II–IV, LV EF 40% |
3,152 |
Losartan 50 mg OD |
Captopril 50 mg TID |
1.5 years |
No |
Primary: all-cause mortality; secondary: composite of sudden cardiac death or resuscitated cardiac arrest |
| Hamroff 1999 (21) |
NYHA III–IV |
33 |
Losartan 50 mg OD |
Placebo |
6 months |
Yes |
Primary: peak aerobic capacity, NYHA functional class; secondary: laboratory safety parameters, doses of concomitant background medications |
| Lang 1997 (29) |
NYHA II–IV, LV EF 45% |
116 |
1) Losartan 25 mg OD; 2) losartan 50 mg OD |
Enalapril 10 mg BID |
12 weeks |
No |
Primary: exercise tolerance, clinical status; secondary: EF |
| Mazayev 1998 (30) |
NYHA II–IV, PCWP 15 mm Hg |
116 |
1) Valsartan 40 mg BID; 2) valsartan 80 mg BID; 3) valsartan 160 mg BID |
1) Placebo;2) Iisinopril 10 mg OD |
4 weeks |
No |
Primary: PCWP, adverse events; secondary: CO, SVR |
| Phase III Int’l 1996 (4) |
NYHA II–IV, EF 40% |
385 |
Losartan 50 mg OD |
Placebo |
12 weeks |
No |
Primary: exercise capacity |
| Phase III US 1995 (4) |
NYHA II–IV, EF 40% |
351 |
Losartan 50 mg OD |
Placebo |
12 weeks |
No |
Primary: exercise capacity |
| RESOLVD 1999 (31) |
NYHA II–IV, LV EF <40%, 6-min walk distance <500 m |
768 |
1) Candesartan 4 mg OD; 2) candesartan 8 mg OD; 3) candesartan 16 mg OD |
1) Enalapril 10 mg BID; 2) placebo |
43 weeks |
No |
Primary: 6-min walk distance, EF, ventricular volume, neurohormone level, QOL, NYHA |
| SPICE 2000 (22) |
NYHA II–IV, LV EF <35% |
270 |
Candesartan 16 mg OD |
Placebo |
12 weeks |
No |
Primary: tolerability; secondary: adverse events, clinical events, QOL, functional status |
| STRETCH 1999 (23) |
NYHA II–III, LV EF 30%–45% |
844 |
1) Candesartan 4 mg OD; 2) candesartan 8 mg OD; 3) candesartan 16 mg OD |
Placebo |
12 weeks |
No |
Primary: exercise time; secondary: clinical status, cardiothoracic ratio, neuroendocrine parameters |
| Tonkon 2000 (24) |
NYHA II–III, LV EF 40% |
109 |
Irbesartan 150 mg OD |
Placebo |
12 weeks |
Yes |
Primary: ETT; secondary: LV EF, clinical status, safety |
| V-HeFT 1999 (25) |
NYHA II–IV, PCWP 15 mm Hg |
83 |
1) Valsartan 80 mg BID; 2) valsartan 160 mg BID |
Placebo |
4 weeks |
Yes |
Primary: PCWP; secondary: hemodynamics, neurohormones |
| Val-HeFT 2001 (18) |
NYHA II–IV, LV EF 40% |
5,010 |
Valsartan 160 mg BID |
Placebo |
23 months |
Yes |
Primary: all-cause mortality, combined all-cause mortality and morbidity (hospitalization, resuscitated sudden death, IV inotropic or vasodilator support) |
| Weber 1997 (26) |
NYHA II–IV |
154 |
Losartan 2.5–50 mg OD |
Placebo |
12 weeks |
No |
Primary: safety |
